DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

Post-LOE

drospirenone; ethinyl estradiol; levomefolate calcium

Teva

ANDAORALTABLET

Approved

Oct 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM (drospirenone; ethinyl estradiol; levomefolate calcium) by Teva. Approved for females of reproductive potential, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product, shortly after discontinuing the product and 1 more indications. First approved in 2016.

Drug data last refreshed 20h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (4)

females of reproductive potential to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product

Worked on DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.